Healios KK (JP:4593) has released an update.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Healios KK has made progress in its application for conditional approval of its MultiStem product for treating Acute Respiratory Distress Syndrome (ARDS) in Japan. Following positive results in Phase 2 studies, the company has reached an agreement with regulatory authorities on manufacturing details and is preparing for commercial production. Plans are underway for further consultation on the clinical aspects of the application in January.
For further insights into JP:4593 stock, check out TipRanks’ Stock Analysis page.
Trending Articles
- ‘Priced for Fantasy,’ Says Investor About Tesla Stock
- ‘Remain Skeptical,’ Says Top Investor About AMD Stock
- The Ford (NYSE:F) Dealership Conundrum: Can Shakeups Pull Ford Back?
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
